{
  "compound": "Cannabis, CBD",
  "condition": "IBD_CROHNS",
  "effect_size": "Variable but generally favorable",
  "study_type": "SYSTEMATIC_REVIEW",
  "source": "NORML:IBD_SYSTEMATIC_REVIEW_001",
  "participants": "3 RCTs (N=93 patients)",
  "year": 2018,
  "notes": "Cannabis and Cannabinoids for IBD: Cochrane Systematic Review",
  "confidence": "medium",
  "abstract": "Limited RCT data but promising signals; remission rates 40-45% vs 10-35% placebo in individual trials"
}